TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04703595

Intervention type: GENETIC
Intervention: To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.
Description: To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions.
Study: NCT06487741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based stretching exercises
Description: The intervention comprises six weeks of daily static stretching exercises (six minutes a day) in accordance with the recommendation of the American College of Sports Medicine. The intervention is self-administered and consists of two bouts of 30-second bilateral static stretches of the knee flexors, hip abductors, and shoulder elevators.
Study: NCT05333757

Intervention type: OTHER
Intervention: Questionnaire
Description: Adults with spinal deformities were asked to complete two questionnaires assessing quality of life
Study: NCT05436041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Diet Goal Setting Clinical Decision Support
Description: Receives Nutri
Study: NCT04526132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours.
Study: NCT05425082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor relearning program
Description: Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy
Description: Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions.
Study: NCT05276726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB 21822
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB 21822
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB 21822
Description: Administered orally
Study: NCT05621109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: Subjects will receive very low-calorie diet for 8-10 weeks to introduce a rapid weight loss of approximately 10%. Once target weight is achieved, participants will be reintroduced to foods to introduce weight stability.~The male will follow the maternal randomization, i.e. weight loss if BMI ≥25 until a BMI of 23 or a weight loss of approximately 10% is obtained.~During weight loss maintenance, subjects will receive dietary counseling to follow a diet high in protein (corresponding to 22-25E%), high fiber and wholegrain while fulfilling the requirements for essential fatty acids, micronutrients and trace elements in accordance with Nordic Nutrition Recommendations (NNR) 2012.~Throughout the study period participants will be encouraged to follow the official recommendations for physical activity as recommended by the Danish health authorities 2022.
Study: NCT05147766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05682066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovalve MR system
Description: Innovalve MR system
Study: NCT04774484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: After the acclimatization session and assessment of eligibility, a graded exercise test (GXT) will be given to the participant. After checking their vitals, the HIIT program will be performed on recumbent cycles. The first two weeks of training will consist of a gradual ramp where subjects will perform a moderate intensity cycling program consisting of a 5-minute warm up followed by progressively longer continuous cycling starting at 15 minutes and progressing up to 30 minutes prior to starting the HIIT training. For the HIIT training subjects will perform 5 minutes of low to moderate steady state cycling to warm up. Following the warm up, the subjects will complete the 4x4 HIIT program. This will consist of 4 minutes of cycling at 85% of the subject's maximum heart rate (HR) followed by 4 minutes of a low intensity cycling period for recovery.
Study: NCT06443437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bee-buzzy vibrating cold application marionette doll
Description: * Bee-buzzy will be attached to the arm of the preschool child (who is included in the bee-buzzy group) by the researchers, where the phlebotomy will be performed on the child. It reduces pain through its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee-buzzy will be tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse will perform a phlebotomy.~* A marionette doll group; while the nurse is going to perform the phlebotomy operation on the preschool child, one of the researchers will try to distract the child by paly with marionette doll. The researchers will receive training in play therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bee-buzzy vibrating cold application marionette doll
Description: * Bee-buzzy will be attached to the arm of the preschool child (who is included in the bee-buzzy group) by the researchers, where the phlebotomy will be performed on the child. It reduces pain through its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee-buzzy will be tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse will perform a phlebotomy.~* A marionette doll group; while the nurse is going to perform the phlebotomy operation on the preschool child, one of the researchers will try to distract the child by paly with marionette doll. The researchers will receive training in play therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Rotuine care
Description: children in control group will receive routine hospital are
Study: NCT05998304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] Yiqibuvir
Description: 600 mg suspension containing 100µCi of \[14C\] Yiqibuvir
Study: NCT05567926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice concentrate (140 ml)
Description: A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blackcurrant juice (placebo)
Description: 140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
Study: NCT06424197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Racial group-targeted messages
Description: Colorectal cancer screening messages targeted towards participants racial group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Racial group-targeted messages
Description: Colorectal cancer screening messages targeted towards participants racial group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explicit Commitment
Description: Indicate explicit commitment to return at home screening kit.
Study: NCT04682392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group
Description: A Delphi Personal Tourniquet system for blood flow restriction (BFR) therapy will be applied to each treatment session for this group. They will do 3-5 exercises with the BFR system on the surgical or both lower extremities for bilateral or unilateral movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL rehab
Description: Standard accelerated ACL protocol
Study: NCT06204081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSO_without cueing
Description: The sole is worn without using the cueing application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSO_cueing
Description: The sole is worn with using the cueing application
Study: NCT05254249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Plantarum IS-10506
Description: Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
Study: NCT04682392

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL rehab
Description: Standard accelerated ACL protocol
Study: NCT06052046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOTAL30 for Astigmatism Contact Lenses
Description: Participants will be refit into TOTAL30 for Astigmatism Contact Lenses and followed for 1 month.
Study: NCT05254249

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
Study: NCT05027152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise. The repetitive task training group will carry out exercises involving upper and lower limbs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive task training
Description: The repetitive task training group will carry out exercises involving upper and lower limbs.
Study: NCT04877847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency therapeutic ultrasound (LOTUS)
Description: Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LOTUS System with Ultrasound Disabled
Description: Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.
Study: NCT06196294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy for solid tumors
Description: Transfer γδT cells into patients for anti-ancer therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy for solid tumors
Description: Transfer γδT cells into patients for anti-ancer therapy.
Study: NCT05630417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feet and Back Massage
Description: Foot massage: Feet are the most neglected organs of people and therefore cause many complaints. Foot massage is a massage applied to the back of the foot, toes, soles of the feet, the muscles between the thumb and little fingers, and the heel, where the muscles between the metatarsal bones are located.~Back massage: Back massage is a non-invasive nursing intervention that can be easily applied by nurses. In back massage application; A 10-minute back massage program applied by Çınar and Eşer (2012) will be applied.
Study: NCT05895201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 600 or 400 (or MTD) mg PO every 12 hours on days -1 to +14 depending on dose level assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 or 1.0 mg/m2 (or MTD) IV push 6 hours after graft infusion completion (day 0), and 72 hours thereafter depending on dose level assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV over 1 hour on days +3 and +4
Study: NCT06453499

Intervention type: OTHER
Intervention: Physical therapy
Description: ultrasound for 5 minutes,Tens and hot packs for 20 minutes, back exercise
Study: NCT05296564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYCLOPHOSPHAMIDE and FLUDARABIN
Description: 1. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
Study: NCT05473312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 28-day PD/Hearth Sessions
Description: Mothers will come together in a home-like setting to rehabilitate their malnourished child (8 dyads/Hearth), learn and practice new feeding and childcare behaviours (during Covid-19: 4 dyads/Hearth). Curriculum and activities will be informed by CAC, CORE Guide and formative research. Two female facilitators will demonstrate, encourage, convey key messages and guide practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental Print Information
Description: The content will be informed by the formative research and CAC, will reinforce Hearth messages, and be adapted for each gender group. Material will be locally produced, engaging, user friendly, and target an illiterate audience (i.e. culturally relevant images with minimal text).
Study: NCT04974658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inter-semispinal plane block
Description: Ultrasound Inter-semispinal plane block in block group
Study: NCT05707819

Intervention type: DRUG
Intervention: Sintilimab (PD-1 Antibody)
Description: Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
Study: NCT04790214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHF Patients
Description: Cardiac rehabilitation program on CHF patients on 06-08 weeks. Program will include: physical aerobic re-training, therapeutic education on CHF, psychological follow-up, nutritional education
Study: NCT06036940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative patient education given with three different methods
Description: To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative patient education given with three different methods
Description: To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
Study: NCT02207127

Intervention type: PROCEDURE
Intervention: MRI, DISE, and Surgery
Description: MRI, DISE, and Surgery
Study: NCT05289869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin
Description: Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin
Description: Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Study: NCT05430646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covered metal ureteral stents
Description: The CMUS is a fully covered, self-expanding, large caliber metal stent. The stent is made of super-elastic nickel-titanium alloy, which maintain lumen patency via providing long-term direct wall support.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tandem DJ stents
Description: Tandem DJ stents represents for two stents side-by-side, which improves the urine flow by better withstanding the compressive tumoral forces and allowing urine to flow between the stents.
Study: NCT01041144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: supporting diabetes patients using Internet communication
Study: NCT05924412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous study drug
Description: 40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline solution
Description: Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
Study: NCT04974658

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Inter-semispinal plane block
Description: Ultrasound Inter-semispinal plane block in block group
Study: NCT04967573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg or 10 mg for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg or 10 mg for 3 months
Study: NCT05049850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
Study: NCT05017246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: -Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: -Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: -Lidocaine infusion 1 mg/kg ideal body weight (IBW)
Study: NCT05427396

Intervention type: DRUG
Group type: OTHER
Intervention: JS004
Description: Usage and dosage: Inject 200mg once every 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Toripalimab Injection
Description: Usage and dosage: Inject 240mg once every 3 weeks
Study: NCT05296564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBI 0201-ESO TCRT
Description: HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
Study: NCT05620264

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear Sample Probe
Description: Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
Study: NCT05131139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Description: Eversense 524 CGM System and ROME CGM System.
Study: NCT06537414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daplusiran/Tomligisiran Dose Level 1
Description: Daplusiran/Tomligisiran dose level 1 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daplusiran/Tomligisiran Dose Level 1
Description: Daplusiran/Tomligisiran dose level 1 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daplusiran/Tomligisiran Dose Level 2
Description: Daplusiran/Tomligisiran dose level 2 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daplusiran/Tomligisiran Dose Level 2
Description: Daplusiran/Tomligisiran dose level 2 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered
Study: NCT05144867

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
Study: NCT05089864

Intervention type: OTHER
Group type: OTHER
Intervention: Stent Placement Timing - Early
Description: Stent placement 5-7 weeks after STAR procedure
Study: NCT06022068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 7 mg taken once per week during 26 weeks.
Study: NCT06342453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Participate in CrA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Participate in art focus group, art-making

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Intervention
Description: Watch videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies